PF03446962
PF03446962 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Asian Phase I Study Of PF-03446962
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
Clinical Trials (6)
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
Asian Phase I Study Of PF-03446962
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6